Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity-determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection

Hepatology

Volumn 25, Issue 3, 1997, Pages 745-749

  Chayama, Kazuaki ^a   Tsubota, Akihito ^a   Kobayashi, Masahiro ^a   Okamoto, Katsura ^b   Hashimoto, Michie ^a   Mlyano, Yukiko ^a   Koike, Hlromi ^a   Kobayashi, Mariko ^a   Koida, Isao ^a   Arase, Yasuji ^a   Saitoh, Satoshi ^a   Suzuki, Yoshiyuki ^a   Murashima, Naoya ^a   Ikeda, Kenji ^a   Kumada, Hlromitsu ^a  

^a TORANOMON HOSPITAL   (Japan)

^b Sumitomo Metal Bioscience   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

LYMPHOBLAST INTERFERON; RECOMBINANT ALPHA INTERFERON;

ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DRUG SENSITIVITY; FEMALE; GENE MUTATION; HEPATITIS C; HUMAN; HUMAN TISSUE; INTRAMUSCULAR DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS TITRATION; VIRUS TYPING;

ADULT; AGED; AMINO ACID SEQUENCE; ANTIVIRAL AGENTS; BASE SEQUENCE; DRUG RESISTANCE; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HEPATITIS, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA;

EID: 0031050892     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.510250342     Document Type: Article

References (12)

1. Dienstag JL. Non-A, non-B hepatitis. I. Recognition, epidemiology, and clinical features. Gastroenterology 1983;85:439-462.
2. Koretz RL, Stone O, Mousa M, Gitnick GL. Non-A, non-B post-transfusion hepatitis-a decade later. Gastroenterology 1985;88:1251-1254.
3. Chayama K, Saitoh S, Arase Y, Ikeda K, Matsumoto T, Sakai Y, Kobayashi M, et al. Effect of interferon administration on serum hepatitis C virus RNA in patients with chronic hepatitis C. HEPATOLOGY 1991;3:1040-1043.
4. Shindo M, Di Bisceglie AM, Hoofnagle JH. Long-term follow-up of patients with chronic hepatitis C treated with α-interferon. HEPATOLOGY 1992;15: 1013-1016.
5. Davis GL. Prediction of response to interferon treatment of chronic hepatitis C. J Hepatol 1994;21:1-3.
6. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, Izumi N, et al. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. J Clin Invest 1995;96:224-230.
7. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, Ogura Y, et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 1996;334:77-81.
8. Chayama K, Tsubota A, Arase Y, Saitoh S, Koida I, Ikeda K, Matsumoto T, et al. Genotypic subtyping of hepatitis C virus. J Gastroenterol Hepatol 1993;8:150-156.
9. Chayama K, Tsubota A, Arase Y, Saitoh S, Ikeda K, Sakai Y, Matsumoto T, et al. Quantitative analysis of hepatitis C virus RNA by competitive nested polymerase chain reaction. J Gastroenterol Hepatol 1993;8:S40-S44.
10. Kwok S, Higuchi R. Avoiding false positives with PCR. Nature 1989;339: 237-238.
11. Tanaka E, Kiyosawa K, Matsumoto A, Kashiwakuma T, Hasegawa A, Mori H, Yanagihara O, et al. Serum levels of hepatitis C virus core protein in patients with chronic hepatitis C treated with interferon alfa. HEPATOLOGY 1996;23:1330-1333.
12. Detmer J, Lagier R, Flynn J, Zayati C, Kolberg J, Collins M, Urdea M, et al. Accurate quantification of hepatitis C virus (HCV) RNA from all HCV genotypes by using branched-DNA technology. J Clin Microbiol 1996;34: 901-907.